Latest Regulation News

Suncorp Group Limited has announced a cash return of capital of AUD 3.00 per share, backed by shareholder and regulatory approvals, with payments scheduled for early March 2025.

Suncorp Group Limited reported a robust half-year result for 1H25, with net profit after tax nearly doubling to $1.1 billion, driven by the sale of Suncorp Bank and strong insurance operations. The company announced a substantial capital return and special dividend, underscoring its disciplined capital management.

Suncorp Group Limited has announced a combined ordinary and special dividend totaling AUD 0.63 per security, fully franked and backed by APRA approval for a capital reduction. The payment is scheduled for mid-March 2025.

Structural Monitoring Systems’ subsidiary AEM has won full US Forest Service approval for its MTP136D radio, enabling deployment across all federally regulated US aerial firefighting aircraft and setting the stage for significant growth in 2025.

Macquarie Group's 3Q25 trading update reveals strong growth in annuity-style businesses offset by a significant decline in markets-facing segments due to subdued commodity markets. The group's capital position remains robust, comfortably exceeding regulatory requirements.

Matsa Resources has advised shareholders to take no immediate action following Patronus Resources’ unsolicited takeover offer, with a formal recommendation expected soon.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

Lanthanein Resources has completed diamond drilling at its Lady Grey Project, targeting a significant EM conductor plate aligned with gold anomalies. Approval for further drilling under a higher-grade anomaly sets the stage for potential resource expansion.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Shekel Brainweigh Ltd has requested an immediate suspension from ASX quotation as it moves towards removal from the official ASX list, raising questions about the company’s future.